GAITHERSBURG, Md., June 24 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25. A topic [...]
SEOUL, June 17 (Korea Bizwire) — South Korea will test treatment and vaccine candidates against the new coronavirus on monkeys this month, the science ministry said Wednesday. Two experimental treatments and one vaccine candidate against the novel coronavirus under development by unidentified firms or research organizations will be tested on monkeys as part of the [...]
WASHINGTON, June 16 (Korea Bizwire) — Amid the evolving global challenges posed by the novel coronavirus pandemic, immunization professionals must now grapple with deploying routine immunization services in a daunting and ever-shifting landscape. In a recent survey of 800 immunization professionals conducted by the World Health Organization (WHO), the Sabin Vaccine Institute (Sabin) and other [...]
GAITHERSBURG, Md., June 8 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at [...]
SEOUL, June 8 (Korea Bizwire) — Remdesivir shortens recovery time for novel coronavirus patients, but the experimental drug conventionally used for treating Ebola has limited efficacy in severe cases, health experts said Monday. Last week, the Ministry of Food and Drug Safety, South Korea’s drug safety watchdog, approved the use of Remdesivir as a treatment [...]
GAITHERSBURG, Md., June 4 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein [...]
SEOUL, June 4 (Korea Bizwire) — A Seoul-based international vaccine research institute said Thursday that it will start clinical trials of a vaccine for the novel coronavirus in South Korea. The first and second phase clinical trials of the COVID-19 vaccine candidate, dubbed INO-4800, are expected to kick off here by the end of this [...]
GAITHERSBURG, Md., May 27 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the acquisition of Praha Vaccines a.s., part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million. The acquisition includes a biologics manufacturing facility and associated assets [...]
GAITHERSBURG, Md., May 25 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. NVX‑CoV2373 includes Novavax’ proprietary [...]
SEOUL, May 19 (Korea Bizwire) – South Korean companies have received funds from the Bill & Melinda Gates Foundation, one of the world’s largest private foundations, to research treatment for COVID-19 after South Korea became a model case in containing the pandemic, with high potential in the information technology (IT) and biopharma industries. SK Bioscience, a local [...]